Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.
Antidepressants require adaptive brain changes before efficacy is achieved, and they may impact the affectively disordered brain differently than the normal brain. We previously demonstrated metabolic disturbances in limbic and cortical regions of the congenitally helpless rat, a model of susceptibility to affective disorder, and we wished to test whether administration of fluoxetine would normalize these metabolic differences. Fluoxetine was chosen because it has become a first-line drug for the treatment of affective disorders. We hypothesized that fluoxetine antidepressant effects may be mediated by decreasing metabolism in the habenula and increasing metabolism in the ventral tegmental area. We measured the effects of fluoxetine on forced swim behavior and regional brain cytochrome oxidase activity in congenitally helpless rats treated for 2 weeks with fluoxetine (5mg/kg, i.p., daily). Fluoxetine reduced immobility in the forced swim test as anticipated, but congenitally helpless rats responded in an atypical manner, i.e., increasing climbing without affecting swimming. As hypothesized, fluoxetine reduced metabolism in the habenula and increased metabolism in the ventral tegmental area. In addition, fluoxetine reduced the metabolism of the hippocampal dentate gyrus and dorsomedial prefrontal cortex. This study provided the first detailed mapping of the regional brain effects of an antidepressant drug in congenitally helpless rats. All of the effects were consistent with previous studies that have metabolically mapped the effects of serotonergic antidepressants in the normal rat brain, and were in the predicted direction of metabolic normalization of the congenitally helpless rat for all affected brain regions except the prefrontal cortex.
Shumake
Jason
J
Department of Psychology and Pharmacology, University of Texas at Austin, TX 78712, USA.
Colorado
Rene A
RA
Barrett
Douglas W
DW
Gonzalez-Lima
F
F
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology; D001931:Brain Mapping / Q000379:methods; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D003576:Electron Transport Complex IV / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D005473:Fluoxetine / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013550:Swimming / Q000523:psychology
D018687:Antidepressive Agents, Second-Generation; D003576:Electron Transport Complex IV; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors
Brain Res. 1980 Jul 21;194(1):117-24
7378832
Biol Psychiatry. 2000 Oct 15;48(8):830-43
11063978
Biol Psychiatry. 2009 Sep 1;66(5):441-50
19539268
J Neurochem. 1979 Jan;32(1):15-22
759566
Behav Brain Res. 2004 Apr 2;150(1-2):217-21
15033295
Am J Psychiatry. 1999 May;156(5):675-82
10327898
Pharmacol Biochem Behav. 2004 May;78(1):165-9
15159146
Biol Psychiatry. 1997 Jan 1;41(1):15-22
8988791
Aust N Z J Psychiatry. 1999 Oct;33(5):642-9
10544987
J Neurosci. 1981 Mar;1(3):285-91
7264720
Psychopharmacology (Berl). 2002 Apr;160(4):353-61
11919662
J Neurosci. 1988 Jun;8(6):1951-61
3385484
J Neurosci. 2010 Apr 28;30(17):5876-83
20427648
Brain Res. 2004 Dec 31;1030(2):267-76
15571675
Neuroreport. 2000 Nov 27;11(17):3793-8
11117493
Psychopharmacol Bull. 1985;21(3):443-6
2994157
Psychiatry Res. 1999 Oct 11;91(3):127-39
10641577
Behav Brain Res. 2005 Nov 7;164(2):222-30
16095730
J Neurochem. 1984 Sep;43(3):724-32
6540296
J Clin Psychiatry. 1999 Sep;60(9):574-9
10520974
Synapse. 2007 Feb;61(2):72-7
17117425
Synapse. 2004 Apr;52(1):73-5
14755634
Br J Pharmacol. 1995 Sep;116(2):1923-31
8528581
Brain Res Mol Brain Res. 1992 Jun;14(1-2):94-100
1353857
Behav Cogn Neurosci Rev. 2003 Sep;2(3):198-221
15006293
Arch Gen Psychiatry. 2009 Aug;66(8):848-56
19652124
Pharmacol Biochem Behav. 2008 May;89(3):456-62
18313125
Neuroscience. 1994 Nov;63(2):559-78
7891865
Neuroscience. 2002;114(2):373-7
12204206
Pharmacol Biochem Behav. 1982 Oct;17(4):841-5
7178192
Psychopharmacology (Berl). 2009 Dec;207(2):315-23
19760282
Psychopharmacology (Berl). 1995 Sep;121(1):66-72
8539342
Nature. 1977 Apr 21;266(5604):730-2
559941
Biol Psychiatry. 2001 Aug 15;50(4):231-7
11522256
Am J Psychiatry. 1996 Feb;153(2):151-62
8561194
Brain Res. 2000 Jan 31;854(1-2):35-41
10784104
Brain Res. 2003 Feb 14;963(1-2):274-81
12560133
Biol Psychiatry. 1999 Nov 1;46(9):1181-91
10560024
Brain Res Brain Res Rev. 2005 Feb;48(1):1-15
15708625
Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277-95
6128769
Neurosci Lett. 2001 Sep 21;311(1):45-8
11585564
Neuroimage. 1999 Aug;10(2):163-72
10417248
Neuropsychopharmacology. 1999 Aug;21(2 Suppl):91S-98S
10432494
Behav Brain Res. 2010 May 1;209(1):183-6
20122969